Expert Review of Endocrinology & Metabolism最新文献

Is metformin therapy limiting the benefits of exercise? 二甲双胍治疗是否限制了运动的益处？

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-12 DOI: 10.1080/17446651.2026.2672989

Steven K Malin

引用次数: 0

What is the role of amylin as an emerging therapeutic agent in obesity? 胰淀素作为一种新兴的治疗肥胖症的药物有什么作用？

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-07 DOI: 10.1080/17446651.2026.2668391

Guillaume Bogaerts, Greta Lommi, Thomas A Lutz

引用次数: 0

Metabolic aspects of polycystic ovary syndrome. 多囊卵巢综合征的代谢方面。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-04 DOI: 10.1080/17446651.2026.2656240

Dimitrios Pappas, Eleni Kandaraki, Aikaterini Kalogirou, Evanthia Diamanti-Kandarakis

{"title":"Metabolic aspects of polycystic ovary syndrome.","authors":"Dimitrios Pappas, Eleni Kandaraki, Aikaterini Kalogirou, Evanthia Diamanti-Kandarakis","doi":"10.1080/17446651.2026.2656240","DOIUrl":"https://doi.org/10.1080/17446651.2026.2656240","url":null,"abstract":"Introduction: Polycystic ovary syndrome (PCOS) is a prevalent multisystem disorder with major reproductive and metabolic consequences. Understanding the interconnected molecular pathways linking insulin resistance (IR), hyperinsulinemia, and hyperandrogenism is crucial, as these mechanisms form the foundation for effective clinical management and targeted therapeutic strategies.Areas covered: This review examines current evidence on the metabolic underpinnings of PCOS, focusing on how IR and compensatory hyperinsulinemia alter ovarian steroidogenesis, impair granulosa cell aromatase activity, and disrupt follicular development. We summarize downstream systemic consequences-including dyslipidemia, impaired glucose tolerance, cardiovascular risk, and nonalcoholic fatty liver disease-while integrating emerging data on environmental disruptors, oxidative stress, and adipose tissue dysfunction. Literature was identified through a comprehensive search of PubMed, Scopus, Google Scholar, and ScienceDirect for studies published between 1985 and 2025, including clinical, experimental, and mechanistic work relevant to metabolic aspects of PCOS.Expert opinion: Clarifying the metabolic and endocrine mechanisms driving both reproductive and systemic dysfunction provides a critical basis for developing targeted therapies capable of improving ovulatory function and long-term cardiometabolic outcomes. Deepening mechanistic insight remains essential for advancing individualized and integrative treatment approaches in this heterogeneous and evolving syndrome.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-17"},"PeriodicalIF":2.8,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New guidelines for premature ovarian insufficiency: a step forward or more hurdles? 卵巢功能不全的新指南：向前迈进一步还是更多障碍？

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-23 DOI: 10.1080/17446651.2026.2662444

Arianna Daneri, Matteo Lambertini

引用次数: 0

The intersection of education and health: schools as a catalyst for childhood obesity prevention. 教育与健康的交集：学校作为儿童肥胖预防的催化剂。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-03-20 DOI: 10.1080/17446651.2026.2647962

Thomas M Barber, Elizabeth V Niven, Peter Tymms

{"title":"The intersection of education and health: schools as a catalyst for childhood obesity prevention.","authors":"Thomas M Barber, Elizabeth V Niven, Peter Tymms","doi":"10.1080/17446651.2026.2647962","DOIUrl":"10.1080/17446651.2026.2647962","url":null,"abstract":"Introduction: The traditional school environment places emphasis on educational outcomes. There is great potential to build on existing work to re-design a school of the future that conflates both educational and healthcare provision for our children. This includes provision for the burgeoning global problem of childhood obesity and its sequelae. Through addressing the health, wellbeing and educational needs of our children, the future school should optimize health, happiness and success in adulthood.Areas covered: We provide a template for a re-designed future school that optimizes the educational, health and wellbeing needs of our children (including the prevention of excessive weight gain) through changes to the physical environment, routine, food, cultural, and learning environments. Pubmed searches: published data on childhood obesity and its association with adulthood obesity, and existing innovations within schools, including those to improve physical activity and healthy eating.Expert opinion: Children experience the world (and school) holistically. We need to align our re-design of schools accordingly. Given the links between health, wellbeing and educational attainment in children, we argue that the future school should ultimately contribute meaningfully toward a healthier, happier and more productive society.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"181-193"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Hellenic study on insulin technique and administration (HELITA). 希腊胰岛素技术与给药研究（HELITA）。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-20 DOI: 10.1080/17446651.2026.2663053

Anastasios Kaisidis, Athanasia Papazafiropoulou, Eleni Papadokostaki, Malamatenia Koymaki, Theocharis Koufakis, Nikolaos Papanas, Kyriakos Kazakos

{"title":"The Hellenic study on insulin technique and administration (HELITA).","authors":"Anastasios Kaisidis, Athanasia Papazafiropoulou, Eleni Papadokostaki, Malamatenia Koymaki, Theocharis Koufakis, Nikolaos Papanas, Kyriakos Kazakos","doi":"10.1080/17446651.2026.2663053","DOIUrl":"10.1080/17446651.2026.2663053","url":null,"abstract":"Background: The Hellenic study on Insulin Technique and Administration (HELITA) is a national questionnaire survey in Greece aiming to assess insulin administration practices among people with diabetes.Research design and methods: The study enrolled 701 insulin-treated adults with type 1 and type 2 diabetes recruited from 40 diabetes care settings. Participants completed a structured questionnaire on insulin administration practices and underwent physical assessment of all injection sites by diabetes educators.Results: Most participants (57.6%) reused insulin pen needles, while 38.9% did not rotate injection sites. Incorrect insulin dose titration was reported by 17.3%, 39.1% used long needles (8 mm), and 30.1% stored insulin incorrectly after first use. Notably, 41.1% had never had their injection sites inspected by healthcare professionals, and lipohypertrophy was diagnosed in 55.1%. Multivariate analysis showed that missed insulin doses (Odds Ratio: 1.73, 95% Confidence Interval: 1.14-2.62, p = 0.01) and lipohypertrophy were associated with poorer glycemic control. Increased risk of lipohypertrophy was observed among participants who did not rotate injection sites, reused needles, or lacked systematic education on insulin administration.Conclusions: Continuous education on insulin injection practices may contribute to improving glycemic control and reducing the risk of lipohypertrophy.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"231-243"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osteoporosis in chronic kidney disease: diagnostic dilemmas and therapeutic controversies. 慢性肾脏疾病骨质疏松：诊断困境和治疗争议。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-03-22 DOI: 10.1080/17446651.2026.2646161

Sukanya Sakthivel, Marie Houmaa Vrist, Bente Langdahl, Hanne Skou Jørgensen

{"title":"Osteoporosis in chronic kidney disease: diagnostic dilemmas and therapeutic controversies.","authors":"Sukanya Sakthivel, Marie Houmaa Vrist, Bente Langdahl, Hanne Skou Jørgensen","doi":"10.1080/17446651.2026.2646161","DOIUrl":"10.1080/17446651.2026.2646161","url":null,"abstract":"Introduction: Fracture risk is substantially increased in chronic kidney disease (CKD) and rises with declining kidney function. Skeletal fragility in CKD results from reduced bone mass, altered bone microarchitecture, and disturbances in mineral and endocrine regulation of bone turnover, leading to high morbidity and mortality.Areas covered: This review summarizes recent data on fracture incidence across CKD stages and discusses current diagnostic challenges, including the role and limitations of fracture risk prediction tools, dual-energy X-ray absorptiometry, and biochemical markers of mineral metabolism and bone turnover. The contribution of advanced imaging techniques to microarchitectural assessment is also addressed. Current guideline-based approaches are reviewed, alongside therapeutic considerations and the limited evidence supporting osteoporosis treatments in advanced CKD. A literature search was performed in Pubmed restricted to clinical studies published from 2015 through 2025 for a contemporary update on the topic. Osteoporosis after kidney transplantation was not included.Expert opinion: In the absence of evidence-based treatment protocols for CKD-associated osteoporosis, fracture prevention should rely on pragmatic individualized risk assessment. Optimization of mineral metabolism and cautious use of bone-targeting therapies in high-risk patients are key components of management strategy. Future studies should prioritize CKD-specific fracture outcomes and validated diagnostic strategies to guide treatment decisions.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"205-216"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome. 普罗扎西兰治疗家族性乳糜微粒血症综合征的疗效评价。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-03-20 DOI: 10.1080/17446651.2026.2646166

Shyann Hang, Robert A Hegele

{"title":"The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome.","authors":"Shyann Hang, Robert A Hegele","doi":"10.1080/17446651.2026.2646166","DOIUrl":"10.1080/17446651.2026.2646166","url":null,"abstract":"Introduction: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder marked by severe hypertriglyceridemia and characteristic clinical manifestations, particularly acute pancreatitis. Conventional triglyceride-lowering therapy is largely ineffective. Apolipoprotein (apo) C-III has emerged as a key therapeutic target to lower triglycerides in FCS.Areas covered: This review compares FCS with more common multifactorial chylomicronemia. We searched PubMed for all English language literature focusing on the search terms 'chylomicronemia,' 'hypertriglyceridemia,' 'APOC3 inhibition,' 'plozasiran,' 'olezarsen,' and 'volanesorsen.' We outline traditional management strategies and their limited role in FCS and explore non-traditional therapies including orlistat, lomitapide, inhibitors of angiopoietin like protein 3 (ANGPTL3), and analogues of fibroblast growth factor 21 (FGF21). The primary focus is on RNA-based gene silencing therapeutics that target apo C-III, particularly the small interfering RNA plozasiran and the allele specific oligonucleotides volanesorsen and olezarsen, highlighting key differences in efficacy and tolerability.Expert opinion: In a phase 3 trial of plozasiran, at 10 months, median placebo-adjusted reductions in apo C-III were approximately -90%, while TG levels were reduced up to -59%. Thus, plozasiran and alternative RNA-based therapeutics directed against APOC3 represent transformational therapies for patients with FCS and related phenotypes characterized by severe recalcitrant hypertriglyceridemia.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"195-204"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review. 肥胖症药物治疗与袖式胃切除术的比较：网络荟萃分析和系统评价。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-12 DOI: 10.1080/17446651.2026.2656247

Zachary Omeh, Tahira Khan, Olalekan Uthman, Thomas M Barber

{"title":"Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.","authors":"Zachary Omeh, Tahira Khan, Olalekan Uthman, Thomas M Barber","doi":"10.1080/17446651.2026.2656247","DOIUrl":"10.1080/17446651.2026.2656247","url":null,"abstract":"Introduction: Tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP1RA) and glucose-dependent insulinotropic-peptide (GIP), has shown efficacy regarding weight-loss.Methods: Systematic review and network meta-analysis of randomized controlled trials. MEDLINE, EMBASE, and Cochrane CENTRAL databases were searched between 2014 and 2024 for trials comparing sleeve gastrectomy (SG), Tirzepatide and other pharmacotherapies to control or each other. Eligible studies: adults with obesity and weight loss outcomes ≥24 weeks. Primary outcome: percentage change total body weight. Secondary outcomes included adverse events. Pairwise and network meta-analyses were performed. Interventions ranked by: P-score, mean difference (MD), 95% confidence intervals (CI).Results: Data from 23 trials (14,293 participants) were analyzed. SG (MD 21.1% TWL, 95% CI 14.2% to 28.0%) and Tirzepatide 10 or 15 mg (MD 21.3% TWL, 95% CI 17.3% to 25.2%) demonstrated statistically equivalent weight-loss efficacy (P-score: 0.84) and had the most favorable effectiveness profiles. Semaglutide 2.4 mg (MD 12.7% TWL) and Liraglutide 3.0 mg (MD 5.1% TWL) showed moderate efficacy, whilst Orlistat showed minimal effect (MD 2.7% TWL, 95% CI -4.2% to 9.6%). Network meta-analysis of adverse events demonstrated that Semaglutide 2.4 mg and Orlistat had the most favorable safety profiles amongst pharmacotherapies.Conclusions: Tirzepatide 10 mg and 15 mg is equivalent to SG regarding weight-loss efficacy.Registration: This paper was registered with PROSPERO (ID: CRD420251016726). Due to institutional academic requirements and checks, registration was completed after the review began, however the review protocol (supplement material S1) was developed prior to the review, provided by the authors, and thoroughly adhered to by the authors.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"217-229"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring actions of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond glucose and obesity control: bone health and osteoporosis. 探索胰高血糖素样肽-1受体激动剂（GLP-1RAs）在血糖和肥胖控制之外的作用：骨骼健康和骨质疏松症。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-07 DOI: 10.1080/17446651.2026.2652305

Athanasios Kasotas, Maria Apostolopoulou

引用次数: 0